Quick Answer
Karyopharm Therapeutics Inc. reported Total Revenue of $146.07 million for fiscal year 2025.
Karyopharm Therapeutics Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $146.07M +0.6% |
$145.24M -0.5% |
$146.03M -7.0% |
$157.07M -25.1% |
$209.82M +94.1% |
$108.08M +164.3% |
| Revenue (ASC 606) | $146.07M +0.6% |
$145.24M -0.5% |
$146.03M -7.0% |
$157.07M -25.1% |
$209.82M +94.1% |
$108.08M +164.3% |
| Net Income | -$196.04M -156.5% |
-$76.42M +46.6% |
-$143.10M +13.4% |
-$165.29M -33.2% |
-$124.09M +36.8% |
-$196.27M +1.7% |
| Diluted EPS | -$17.93 -28.1% |
-$14.00 +25.5% |
-$18.79 -830.2% |
-$2.02 -22.4% |
-$1.65 +39.3% |
-$2.72 |
| Total Assets | $108.42M -34.1% |
$164.42M -31.6% |
$240.44M -32.9% |
$358.17M +17.3% |
$305.31M -2.5% |
$313.05M +6.1% |
| Cash and Equivalents | $60.54M -3.1% |
$62.48M +19.6% |
$52.23M -61.4% |
$135.19M -29.0% |
$190.46M +121.7% |
$85.92M -33.3% |
| Stockholders Equity | -$292.93M -57.5% |
-$186.02M -36.6% |
-$136.21M -717.8% |
-$16.66M +79.1% |
-$79.67M -257.6% |
$50.55M +1.6% |
| R&D Expense | $125.62M -12.3% |
$143.23M +3.2% |
$138.75M -6.7% |
$148.66M -7.6% |
$160.84M +6.6% |
$150.81M +23.3% |
| Operating Income | -$90.71M +24.1% |
-$119.44M +7.8% |
-$129.54M +8.9% |
-$142.20M -44.7% |
-$98.27M +42.8% |
-$171.85M +9.2% |
| Shares Outstanding | 18.31M +117.7% |
8.41M -92.7% |
114.92M +1.5% |
113.21M +49.5% |
75.75M +2.5% |
73.92M +13.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $44.04M | +13.6% | +16.1% |
| Revenue (ASC 606) | September 30, 2025 | $44.04M | +13.6% | +16.1% |
| Net Income | September 30, 2025 | -$33.13M | -3.3% | +11.1% |
| Diluted EPS | September 30, 2025 | -$3.82 | +0.8% | +11.6% |
| Total Assets | September 30, 2025 | $96.23M | -49.2% | -8.2% |
| Cash and Equivalents | September 30, 2025 | $37.67M | -48.3% | -2.7% |
| Stockholders Equity | September 30, 2025 | -$269.26M | -68.7% | -12.7% |
| R&D Expense | September 30, 2025 | $30.54M | -15.5% | -6.8% |
| Operating Income | September 30, 2025 | -$15.22M | +42.1% | +37.6% |
| Shares Outstanding | September 30, 2025 | 8.70M | -93.1% | +0.6% |
- Karyopharm Therapeutics Inc. reported Total Revenue of $146.07 million for fiscal year 2025.
- Karyopharm Therapeutics Inc. showed an increase of +0.6% in Total Revenue compared to the prior fiscal year.
- Karyopharm Therapeutics Inc. reported Revenue (ASC 606) of $146.07 million for fiscal year 2025.
- Karyopharm Therapeutics Inc. showed an increase of +0.6% in Revenue (ASC 606) compared to the prior fiscal year.
- Karyopharm Therapeutics Inc. reported Net Income of -$196.04 million for fiscal year 2025.
- Karyopharm Therapeutics Inc. showed a decrease of -156.5% in Net Income compared to the prior fiscal year.
- Karyopharm Therapeutics Inc. reported Diluted EPS of $17.93 per share (loss) for fiscal year 2025.
- Karyopharm Therapeutics Inc. showed a decrease of -28.1% in Diluted EPS compared to the prior fiscal year.
- Karyopharm Therapeutics Inc. reported Total Assets of $108.42 million for fiscal year 2025.
- Karyopharm Therapeutics Inc. showed a decrease of -34.1% in Total Assets compared to the prior fiscal year.
- Karyopharm Therapeutics Inc. reported Cash and Equivalents of $60.54 million for fiscal year 2025.
- Karyopharm Therapeutics Inc. showed a decrease of -3.1% in Cash and Equivalents compared to the prior fiscal year.
- Karyopharm Therapeutics Inc. reported Stockholders Equity of -$292.93 million for fiscal year 2025.
- Karyopharm Therapeutics Inc. showed a decrease of -57.5% in Stockholders Equity compared to the prior fiscal year.
- Karyopharm Therapeutics Inc. reported R&D Expense of $125.62 million for fiscal year 2025.
- Karyopharm Therapeutics Inc. showed a decrease of -12.3% in R&D Expense compared to the prior fiscal year.
- Karyopharm Therapeutics Inc. reported Operating Income of -$90.71 million for fiscal year 2025.
- Karyopharm Therapeutics Inc. showed an increase of +24.1% in Operating Income compared to the prior fiscal year.
- Karyopharm Therapeutics Inc. reported Shares Outstanding of 18.31 million shares for fiscal year 2025.
- Karyopharm Therapeutics Inc. showed an increase of +117.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: